

TRUST BOTOX®

(Botulinum Toxin Type A)

TRIED AND TESTED IN TREATING CHRONIC MIGRAINE^{1,2,3,22}

PROVEN EFFICACY:

- A continued reduction in headache days from first treatment up to **2 years** from baseline²
- **9 years of real-world experience** consistently demonstrating a reduction in headache days from baseline³⁻²²
- >60% of chronic migraine patients demonstrated a **clinically meaningful improvement in comorbid depression and anxiety scores** at 3 months (n=150)²³



ESTABLISHED SAFETY & TOLERABILITY EXPERIENCE FROM 30 YEARS OF USE IN A RANGE OF CONDITIONS^{1,2,24,25,26}

“ I used to feel life was going on around me. Now I feel part of it all. ”

BOTOX® (Botulinum toxin type A) Abridged Prescribing Information C: Clostridium botulinum toxin type A. **I:** Treatment of blepharospasm associated with dystonia including benign essential blepharospasm, hemifacial spasm & Vith nerve disorder in patients >12 yr; correction of strabismus in patients >12 yr; spasmodic torticollis (cervical dystonia) in adults; dynamic equinus foot deformity due to spasticity in paed cerebral palsy >2 yr. **Management of focal spasticity** including wrist & hand disability due to upper limb spasticity associated with stroke in adults; severe hyperhidrosis of the axillae not responding to topical treatment with antiperspirant or anticholinergics. **Prophylaxis of headaches** in adults with chronic migraine (headaches on at least 15 days/month of which at least 8 days are with migraine). **Treatment of urinary incontinence** due to neurogenic detrusor overactivity (NDO) assoc. with multiple sclerosis or spinal cord injury in adults with inadequate response or intolerant of anticholinergic medication. **Treatment of overactive bladder (OAB)** with symptoms of urinary incontinence, urgency, and frequency, in adult patients who have an inadequate response to or are intolerant of an anticholinergic medication. **Temporary improvement in the appearance of upper facial rhytides** (glabellar lines, crow's feet and forehead lines) in adults. **Temporary treatment of glabellar lines** associated with computers &/or procerus muscle activity in adults <65 yr. **D:** **Blepharospasm** Initially, inj 1.25-2.5u into the medial & lateral orbicularis oculi of the upp lid & into the lateral pre-tarsal orbicularis oculi of the lower lid. **Max:** 100 u/12 wk. **Hemifacial spasm or Vith nerve disorders** As for unilateral blepharospasm. **Max:** 200u/2 mth. **Strabismus** Vertical muscles & horizontal strabismus of <20 prism diopters: 1.25-2.5u in any 1 muscle. Horizontal strabismus of 20-50 prism diopters: 2.5-5u in any 1 muscle. **Parastent Vith nerve palsy** of >1 mth: 1.25-2.5u in the medial rectus muscle. **Max:** 25u as single inj for any 1 muscle. **Cervical dystonia** 25-300u. Initial dosing should begin at lowest effective dose. **Max:** 6u/kg/2mth. **Equinus foot deformity due to spasticity in paed cerebral palsy** 4u/kg into each medial & lateral heads of the gastrocnemius muscle. **Max:** 200u at any single tx session. **Focal spasticity in adults** Biceps brachii: 100-200u up to 4 sites; flexor digitorum profundus & flexor digitorum sublimis: 15-50u 1-2 sites; flexor carpi radialis: 15-60u 1-2 sites; flexor carpi ulnaris: 10-50u 1-2 sites; adductor pollicis & flexor pollicis longus: 20u 1-2 sites; gastrocnemius medial head: 75 units divided in 3 sites; gastrocnemius lateral head: 75 units divided in 3 sites; soleus: 75 units divided in 3 sites; tibialis posterior: 75 units divided in 3 sites; flexor hallucis longus: 50 units divided in 2 sites; flexor digitorum longus: 50 units divided in 2 sites; flexor digitorum brevis: 25 units in 1 site. **Hyperhidrosis of the axilla** 50u intradermally to each axilla, evenly distributed in multiple sites 1-2 cm apart. **Chronic migraine** 155u to 195u administered intramuscularly with 5u inj/site. Inj should be divided across 7 specific head/neck muscle areas as specified in the PI. **NDO** 200u inj into detrusor muscle. **OAB** 100 u inj into the detrusor muscle by cystoscopy. **Glabellar lines** 4u/0.1 ml, administered in each of 3 inj sites, 2 in each corrugator muscle & 1 in procerus muscle. **Total dose:** 20u. **Crow's feet** 2-6u/inj site bilaterally at 3 sites in the lateral aspect of orbicularis oculi. **Total dose for crow's feet:** 6-18 units per side. **Forehead lines** 2-6u/inj site IM at 4 sites in frontalis muscle. **Total dose:** 8-24u. **CB:** Myasthenia gravis or Eaton-Lambert syndrome, infection at proposed inj site. **For treatment of bladder dysfunction:** Acute UTI, acute urinary retention not routinely performing clean intermittent self-catheterization. **SP:** Inflammation at proposed inj site, excessive weakness or atrophy in the target muscles, Amyotrophic lateral sclerosis, disorders causing peripheral neuromuscular dysfunction, patient at risk of angle-closure glaucoma. **Caution:** Carefully perform cystoscopy (for bladder treatment). **Pregnancy, lactation, Children <12 yr, Elderly.** **AR:** Localized pain, tenderness &/or bruising; local weakness, UTI & urinary retention in bladder dysfunction patients. **Rarely,** skin rash (including erythema multiforme, urticaria & pruriticiform eruption), pruritis, allergic reaction. **Dr:** Effects potentiated by aminoglycosides or other drugs that interfere with neuromuscular transmission; other muscle relaxants. **RP:** Val 50u x1%; 100u x1%. Please see BOTOX® full prescribing information before prescribing. **Further information** is available upon request.

REFERENCES: 1. BOTOX® local approved PI. 2. Blumenfeld AM, et al. J Headache Pain. 2016;19(1):13. 3. Rhull M, et al. J Headache Pain. 2014;15:54. 4. Stark C, et al. J Headache Pain. 2019;20:81. <https://doi.org/10.1186/s10194-019-1000-z>. 5. Lee MJ, et al. J Neuro Sci. 2016;362:51-54. 6. Byun J, et al. J Clin Neurosci. 2017;13(1):98-100. 7. Negro A, et al. Springerplus. 2015;4:826. 8. Negro A, et al. J Headache Pain. 2016;17:1. 9. Liu C, et al. Neuro Sci. 2014;352(suppl 1):175-176. 10. Koleva K, et al. J Neural Transm. 2016;122(5):533-540. 11. Grazzi L, et al. Neuro Sci. 2015;362(suppl 1):33-35. 12. Grazzi L, Neuro Sci. 2017;38(suppl 1):141-143. 13. Guazzoni S, et al. J Headache Pain. 2016;17:48. 14. Russo M, et al. Neuro Sci. 2016;37(7):1127-1131. 15. Santoro A, et al. Neuro Sci. 2017;38(10):1779-1789. 16. Buluze A, et al. Neurobiol. 2016;7(1):13-15. 17. Camacho-Morales E, et al. Pain. 2015;156(5):820-824. 18. Pedraza M, et al. Springerplus. 2015;4:176. 19. Acua-Rapun L, et al. J Headache Pain. 2016;17:112. 20. Demiryunk BE, et al. Neuro Sci. 2016;37:1779-1784. 21. Aydinli B, et al. J Headache Pain. 2017;18(1):23. 22. Wells M, et al. J Headache Pain. 2016;17(1):64. 23. Blumenfeld AM, et al. J Neural Neurosurg Psychiatry. 2019;90(2):353-360. 24. Allergan. Data on file. INT0423/0016(1). 2018. 25. Allergan. Data on file. INT0572/2016(2). 2019. 26. Aurora SK, et al. Headache. 2011;51(9):1358-1373.

For healthcare profession use only.



Allergan Singapore Pte Ltd
20 Pagar Piering Road, Mapletree Business City, West Building, #09-25, Singapore 117439.
Tel: +65 6747 7077 Fax: +65 6276 8157

